NCT06751251View on ClinicalTrials.gov

The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2026

Conditions
SarcomaBiomarkersProgression
Interventions
DIAGNOSTIC_TEST

IHC: Immunohistochemistry

Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

GENETIC

RNA-seq

RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06751251 - The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination | Biotech Hunter | Biotech Hunter